Zacks Investment Research
02 Jun 2026, 23:15 UTC · 2h ago
Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade
Search tags
Zacks Investment Research
02 Jun 2026, 23:15 UTC · 2h ago
Search tags
Story key points
4 claims · impact-rated
Medpace is forecasted to report a quarterly EPS of $4.08, a 31.61% increase year-over-year. — Strong projected earnings growth typically drives positive sentiment for a specific equity.
+0.40Medpace's quarterly revenue is predicted to reach $678.51 million, up 12.47% from the previous year. — Double-digit revenue growth indicates scaling business operations and healthy demand.
+0.30Medpace has a Forward P/E ratio of 26.5, which is a premium compared to the industry average of 15.1. — A high valuation premium relative to peers can make a stock more susceptible to corrections if growth slows.
-0.20Medpace is currently assigned a Zacks Rank #3 (Hold). — A 'Hold' rating suggests a neutral outlook with no immediate catalyst for significant price movement.
Continue reading
6 related stories
Ticker attribution
Model heads
The company shows strong forecasted EPS and revenue growth and outperformed the S&P 500 over the previous month.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
0 dimensions · 9 clusters
No impact vector found for this article yet.
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Zacks Investment Research
2h ago
